Clinical Research Directory
Browse clinical research sites, groups, and studies.
18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
Sponsor: Taizhou Hospital
Summary
The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.
Official title: A Multicenter Phase II Study of 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
93
Start Date
2022-01-01
Completion Date
2029-06-30
Last Updated
2023-02-21
Healthy Volunteers
No
Conditions
Interventions
Reduced dose
The patients with CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
Conventional dose
The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
Chemotherapy
The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.
Locations (4)
Taizhou Central Hospital
Taizhou, Zhejiang, China
Taizhou Hospital
Taizhou, Zhejiang, China
Taizhou Cancer Hospital
Taizhou, Zhejiang, China
Taizhou Enze Medical Center(Group) Enze Hospital
Taizhou, Zhejiang, China